drugID,ctStudyTitle,ctStudyUrl,ctStudyOutcome
drug0,Effects of Different Doses of Aspirin on Pathophysiological Markers in Type 2 Diabetes|The Effects of Omega-3 Fatty Acids on Aspirin Resistance|Effect of Aspirin on Mammogram Density in Healthy Postmenopausal Women With a Moderate or High Level of Breast Density|Platelet Hyperreactivity to Aspirin and Stroke|Comparative Pharmacokinetics Study of Clopidogrel and Aspirin Fixed-dose Combination Versus Separate Combination|Comparative Pharmacokinetics Study of Clopidogrel and Aspirin Fixed-dose Combination Versus Separate Combination-2nd Trial|The Effect of Aspirin Desensitization on Patients With Aspirin-exacerbated Respiratory Diseases|Mechanism Based Resistance to Aspirin|Aspirin Responsiveness in Women at Risk for Cardiac Events,http://clinicaltrials.gov/show/NCT00898950|http://clinicaltrials.gov/show/NCT00771914|http://clinicaltrials.gov/show/NCT00470561|http://clinicaltrials.gov/show/NCT00766896|http://clinicaltrials.gov/show/NCT01663038|http://clinicaltrials.gov/show/NCT01496261|http://clinicaltrials.gov/show/NCT01867281|http://clinicaltrials.gov/show/NCT00948987|http://clinicaltrials.gov/show/NCT00818337,"Change in markers of oxidative stress, endothelial function, glycaemic control, and insulin resistance|the Difference Between the Time to Clot Formation in Seconds at Baseline and After Each Treatment|Comparison of  the effect of acetylsalicylic acid (aspirin) vs placebo on mammographic density|Correlation between platelet hyperreactivity and the sum of clinical outcomes (sum of death, TIA, stroke and acute coronary syndromes) in 3, 12, 24, and 36 months|Cmax of clopidogrel/acetylsalicylic acid|Assess the pharmacokinetic characteristics of clodiogrel/acetylsalicylic acid.|Change in SNOT-22 scores from Baseline|Arachidonic acid induced platelet aggregation|Number of Women Aspirin Resistant"
drug1,"Topiramate for Alcohol and Cocaine Dependence|Modafinil and Naltrexone to Reduce Cocaine and Alcohol Dependence|Effect of Zonisamide on Cocaine Reinforcement, Craving, and Relapse|Topiramate to Reduce Cocaine Dependence|Study of Safety and Potential Efficacy of SYN117 in Cocaine Dependent Volunteers|Modafinil - Escitalopram Study for Cocaine Dependence|Progesterone for Postpartum Cocaine Relapse|Pramipexole as a Treatment for Cocaine Dependence|Brain Imaging Study of the Effects of Modafinil in Cocaine Addiction|The Effects of Doxazosin on the Cardiovascular and Subjective Effects of Cocaine",http://clinicaltrials.gov/show/NCT00167245|http://clinicaltrials.gov/show/NCT00142818|http://clinicaltrials.gov/show/NCT01137890|http://clinicaltrials.gov/show/NCT00223626|http://clinicaltrials.gov/show/NCT00656357|http://clinicaltrials.gov/show/NCT01601730|http://clinicaltrials.gov/show/NCT01249274|http://clinicaltrials.gov/show/NCT01651377|http://clinicaltrials.gov/show/NCT00701532|http://clinicaltrials.gov/show/NCT01062945,"Percent of Participants Abstinent From Cocaine During Last 3 Weeks of 13 Week Trial|Cocaine Use (Measured by Timeline Follow Back and Urine Screen at Week 14)|subjective and objective measures of drug effect|Cocaine-induced mood changes|Determine the safety of treatment with SYN117 in cocaine-dependent volunteers by measuring hemodynamic and subjective effects of administration of ascending doses of cocaine(10mg, 20mg, 40mg)and  placebo during treatment with ascending doses of SYN117.|The effects of modafinil and/or escitalopram and cocaine on cardiovascular measures|Decreased use of cocaine|The effects of pramipexole and cocaine on cardiovascular measures|Decreased DAT occupation rates in the modafinil group versus placebo from day 3 to day  of cocaine detoxification.|The effects of treatment with doxazosin on cardiovascular effects after administration of ascending doses of cocaine (0, 20mg, and 40mg) and a placebo dose."
